Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.

Front Nutr · 2025 · PMC11973083 · PMID 40196017

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally insignificantno p-value reported

Furthermore, the per-protocol analyses also showed a significant difference in clinical response, with an RR of 2.04 (95% CI: 1.30, 3.20; Z: 3.08, P: 0.002); however, the difference between curcumin and placebo was marginally insignificant for clinical remission, with an RR of 3.04 (95% CI: 0.93, 9.96; Z: 1.84, P: 0.07).

also in 168 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.